Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2019 Sep 23. pii: clincanres.2329.2019. doi: 10.1158/1078-0432.CCR-19-2329. [Epub ahead of print]

PMID:
31548341
2.

FDA Approval Summary: Glasdegib for Newly Diagnosed Acute Myeloid Leukemia.

Norsworthy KJ, By K, Subramaniam S, Zhuang L, Del Valle PL, Przepiorka D, Shen YL, Sheth CM, Liu C, Leong R, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2019 Oct 15;25(20):6021-6025. doi: 10.1158/1078-0432.CCR-19-0365. Epub 2019 May 7.

PMID:
31064779
3.

FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.

Norsworthy KJ, Luo L, Hsu V, Gudi R, Dorff SE, Przepiorka D, Deisseroth A, Shen YL, Sheth CM, Charlab R, Williams GM, Goldberg KB, Farrell AT, Pazdur R.

Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28.

PMID:
30692099
4.

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.

Krauss AC, Gao X, Li L, Manning ML, Patel P, Fu W, Janoria KG, Gieser G, Bateman DA, Przepiorka D, Shen YL, Shord SS, Sheth CM, Banerjee A, Liu J, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R.

Clin Cancer Res. 2019 May 1;25(9):2685-2690. doi: 10.1158/1078-0432.CCR-18-2990. Epub 2018 Dec 12.

PMID:
30541745
5.

FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.

Jen EY, Ko CW, Lee JE, Del Valle PL, Aydanian A, Jewell C, Norsworthy KJ, Przepiorka D, Nie L, Liu J, Sheth CM, Shapiro M, Farrell AT, Pazdur R.

Clin Cancer Res. 2018 Jul 15;24(14):3242-3246. doi: 10.1158/1078-0432.CCR-17-3179. Epub 2018 Feb 23.

6.

Assessment of immunotoxicity in female Fischer 344/N and Sprague Dawley rats and female B6C3F1 mice exposed to hexavalent chromium via the drinking water.

Shipkowski KA, Sheth CM, Smith MJ, Hooth MJ, White KL Jr, Germolec DR.

J Immunotoxicol. 2017 Dec;14(1):215-227. doi: 10.1080/1547691X.2017.1394932.

PMID:
29141474
7.

Effects of modulating in vivo nitric oxide production on the incidence and severity of PDE4 inhibitor-induced vascular injury in Sprague-Dawley rats.

Sheth CM, Enerson BE, Peters D, Lawton MP, Weaver JL.

Toxicol Sci. 2011 Jul;122(1):7-15. doi: 10.1093/toxsci/kfr082. Epub 2011 Apr 16.

PMID:
21498876
8.

Immunotoxicity of dibromoacetic acid administered via drinking water to female B₆C₃F₁ mice.

Smith MJ, Germolec DR, Luebke RW, Sheth CM, Auttachoat W, Guo TL, White KL Jr.

J Immunotoxicol. 2010 Oct-Dec;7(4):333-43. doi: 10.3109/1547691X.2010.519744. Epub 2010 Oct 19.

PMID:
20958156
9.

Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells.

Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL Jr, Gewirtz DA.

Breast Cancer Res Treat. 2010 Nov;124(2):349-60. doi: 10.1007/s10549-010-0765-7. Epub 2010 Feb 13.

PMID:
20155316
10.

Comparison of primary immune responses to SRBC and KLH in rodents.

White KL Jr, Sheth CM, Peachee VL.

J Immunotoxicol. 2007 Apr;4(2):153-8. doi: 10.1080/15476910701337688.

PMID:
18958724

Supplemental Content

Loading ...
Support Center